mRNA Medicine and Spatiotemporal Delivery Advance Cardiovascular Therapy

Cardiovascular disease remains the leading cause of global mortality, prompting urgent efforts to explore novel therapeutic approaches. The remarkable success of mRNA technology brings new possibilities for CVD treatment, with numerous preclinical studies establishing proof-of-concept, and several have advanced into clinical trials. In parallel, spatiotemporal drug delivery systems for myocardial infarction are evolving into integrative, multifunctional constructs that choreograph therapeutic interventions in synchrony with the heart’s complex repair mechanisms.

Leveraging cumulative experience in mRNA therapeutics, improved understanding of cardiovascular pathophysiology and developments in nanotechnology, genome editing and RNA synthetic biology, mRNA medicine presents promising opportunities for addressing CVDs. The source material describes advancements of mRNA-based biotechnologies for CVDs, including mRNA modifications, mRNA delivery platforms, mRNA-encoded genomic and epigenomic editing, and mRNA-based chimeric antigen receptors for immune cell engineering. It also summarizes preclinical and clinical applications of mRNA medicine in hypercholesterolemia, atherosclerosis, ischemic cardiac injury, cardiac fibrosis and cardiac amyloidosis.

In myocardial infarction, future cardiac drug delivery systems are designed to move beyond simple single-phase release, progressing toward hierarchically programmed delivery schedules that correspond with the sequential stages of myocardial healing: inflammation, proliferation, and remodeling. By tuning the release of immunomodulatory agents, angiogenic factors, and antifibrotic molecules to match the evolving biological milieu, these systems aim to minimize off-target effects and amplify cumulative therapeutic gains. Achieving this level of control is increasingly embedded into the biomaterials themselves, using controlled degradation kinetics, compartmentalized architectures, and multi-responsive chemistries.

The integration of bioelectrical and biomechanical cues represents another frontier in advanced cardiac delivery systems. Emerging biomaterials with electroconductive properties and electroactive scaffolds are being engineered not just to deliver therapeutic molecules, but also to restore electromechanical continuity across damaged myocardial tissue. The source article says these interfaces enhance electrical signal propagation, encourage cardiomyocyte alignment, and foster maturation, while electroactive platforms also offer possibilities for stimulus-responsive drug release regulated by electrical or mechanical signals.

The source material also describes a move toward cell-free yet biologically intelligent therapeutic platforms. Engineered extracellular vesicles, membrane-coated nanoparticles, and exosome-mimetic constructs are being developed to replicate instructive and paracrine signaling functions of living cells, and can be integrated into hydrogels, microneedle arrays, or injectable depots tailored for acute myocardial infarction and chronic heart failure settings. Clinical translation is linked to compatibility with minimally invasive delivery techniques, including catheter-based, percutaneous, and image-guided deployment methods, as well as paintable hydrogels, injectable matrices, and microneedle interfaces.

As the complexity of spatiotemporal delivery systems escalates, artificial intelligence, machine learning, and predictive computational modeling are emerging as tools to integrate multi-omics datasets, high-resolution imaging inputs, and longitudinal biomarker profiles, refine material selection and tune release kinetics. The mRNA source article similarly highlights challenges and future directions for bench-to-bedside translation of mRNA technology in the field of cardiovascular disease.